Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Breast
Descriptor: Reviews

Reference Number: 1007
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-14 (2009)
PubMed link      E-mail link

Reference Number: 1210
Locatelli A, Lofgren KA, Daniel AR, Castro NE, Lange CA. Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Horm Cancer. 3, 14-25 (2012)
PubMed link      E-mail link

Reference Number: 1543
Al Moustafa AE. Epithelial-mesenchymal transition and its regulators are major targets of triple-negative breast cancer. Cell Adh Migr. 7, 424-5 (2013)
PubMed link      E-mail link

Reference Number: 1641
Gaule PB, Crown J, O'Donovan N, Duffy MJ. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? Expert Opin Ther Targets. 18, 999-1009 (2014)
PubMed link      E-mail link

Reference Number: 1667
Liu S. HGF-MET as a breast cancer biomarker. Aging (Albany NY). 7, 150-1 (2015)
PubMed link      E-mail link

Reference Number: 1861
Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 17, 52 (2015)
PubMed link      E-mail link